Data from more than 2.6 million sleep apnea patients reveals 75
percent adherence rate when patients are remotely monitored
Separate study shows enrolling in resupply programs increases
long-term device usage, and decreases termination rates
SAN DIEGO--(BUSINESS WIRE)--
Remote patient monitoring and resupply programs have been shown to
improve patient adherence to positive airway pressure (PAP) therapy,
according to two separate studies presented by ResMed (NYSE: RMD, ASX:
RMD) this week at the ATS 2018 International Conference.
Remote monitoring boosts compliance
In the first study, medXcloud, a ResMed-assembled group of healthcare
key opinion leaders, examined de-identified data of more than 2.6
million U.S. PAP users from ResMed’s world-leading remote monitoring
network, AirView. Using this big data approach, researchers observed
excellent adherence among patients initiating PAP therapy: 75 percent
achieved the CMS compliance threshold.* This rate compares very
favorably with that of non-cloud-connected PAP therapy and other chronic
medical therapies – both around 50 percent. Plus, the large sample
suggests that the findings are generalizable and likely to reflect
real-world clinical care.
Resupply program boosts long-term compliance
In a separate study of more than 100,000 well-matched PAP users, ResMed
and collaborating researchers found that over a one-year period, those
enrolled in a resupply program slept 5.6 hours on PAP each night,
compared to 4.5 hours/night for those not enrolled (a 24 percent
increase). Resupply patients were also significantly less likely to
terminate PAP altogether, with a one-year termination rate probability
of 16.1 percent for the resupply group, compared with 33.8 percent for
the control group.
“These two studies demonstrate significantly effective ways to help
patients achieve 90-day compliance with cloud-based remote monitoring
and to keep them compliant over the long term with mask resupply
programs,” said Adam Benjafield, researcher on both studies and ResMed’s
vice president of Medical Affairs. “This is why every new ResMed PAP
device has cloud connectivity without any setup required by the
clinician or user, and why we advocate for patients to be enrolled in
mask resupply programs to maximize their long-term adherence to improve
health outcomes.”
Details about both studies
Real World PAP Adherence: Results from a Big Data Approach in More
than Two Million Patients: ResMed examined de-identified AirView
database (ResMed Corp., USA) data in >2.6M U.S. sleep-disordered
breathing (SDB) patients on PAP therapies (40.9% CPAP, 49.9% APAP, 9.2%
Bilevel) to investigate 90-day adherence. To be included, patients were
enrolled in the U.S. AirView database by their healthcare provider and
used a single therapy mode to treat SDB available on the wirelessly
connected AirSense or AirCurve 10 platforms. Data were extracted for
adult patients (age >18 years) enrolled during the period 1 October 2014
to 31 October 2017, which contained at least one session with device
usage ≥1 hour in the first 90 days. Researchers defined the primary
outcome as adherence using CMS criteria. The study was reviewed by an
Institutional Review Board (IRB) and deemed exempt from IRB oversight.
Positive Airway Pressure (PAP) Therapy Compliance on a Resupply
Program: A Retrospective Analysis: De-identified data from a patient
billing database (Brightree) and de-identified device data from a
telemonitoring database (AirView) were sent to a third-party independent
statistician who provided the anonymized analyses and findings. Patients
were included if they met the following criteria: initiation of PAP
therapy between 1 July 2014 and 17 June 2016; achievement of CMS
compliance; therapy management via telemonitoring (AirView; ResMed).
Patients who started a resupply program (resupply group) were propensity
matched 1:1 with patients who did not start a resupply program. The
resupply program replenished a patient’s PAP therapy equipment (mask
systems and/or cushions). The primary endpoint was adherence, measured
by average device usage hours per day, in the resupply versus control
group. Secondary endpoints include other measures of adherence and
device usage, and the rate of therapy termination (zero usage in the
previous 30 days). The study protocol was reviewed by an Institutional
Review Board and deemed exempt from IRB oversight.
About ResMed
ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company
with more than 5 million cloud-connected devices for daily remote
patient monitoring, changes lives with every breath. Its award-winning
devices and software solutions help treat and manage sleep apnea,
chronic obstructive pulmonary disease and other respiratory conditions.
Its 6,000-member team strives to improve patients’ quality of life,
reduce the impact of chronic disease and save healthcare costs in more
than 120 countries. ResMed.com
*CMS compliance, as defined by the U.S. Center for Medicare & Medicaid
Services, requires using CPAP usage of 4 hours a night for 70% of nights
in a 30-day span within the first 90 days of therapy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180522005020/en/
Source: ResMed